Protara Therapeutics (TARA) Notes Payables (2013 - 2020)

Protara Therapeutics' (TARA) quarterly Notes Payables came in at $370793.0 in Q3 2020, down 60.0% on a QoQ basis from $926983.0 in Q2 2020.

Protara Therapeutics (TARA) Notes Payables (2013 - 2020) Analysis & Trends

Protara Therapeutics (TARA) has 2 years of Notes Payables data on file, last reported at $370793.0 in Q3 2020.

On a quarterly basis, Notes Payables changed N/A year-over-year to $370793.0 in Q3 2020; TTM through Sep 2020 was $370793.0, a N/A change from a year earlier, with the FY2013 full-year figure at $1.4 million, changed N/A from the prior year.
Notes Payables for Q3 2020 stood at $370793.0, down from $926983.0 in the prior quarter.
Over the last five years, Notes Payables for TARA reached as high as $1.3 million in Q1 2020 and fell as low as $370793.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Protara Therapeutics	2.25 Mn	2.25 Mn	-

Download Data